Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35


Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma.

Rajan A, Heery CR, Thomas A, Mammen AL, Perry S, O'Sullivan Coyne G, Guha U, Berman A, Szabo E, Madan RA, Ballester LY, Pittaluga S, Donahue RN, Tsai YT, Lepone LM, Chin K, Ginty F, Sood A, Hewitt SM, Schlom J, Hassan R, Gulley JL.

J Immunother Cancer. 2019 Oct 21;7(1):269. doi: 10.1186/s40425-019-0723-9.


Acquisition of Skills in Operative Dentistry Following a Contemporary Technique Skills Course: A Retrospective Study.

Sadid-Zadeh R, Arany H, Guha U, Haraszthy V.

J Dent Educ. 2019 Aug;83(8):959-965. doi: 10.21815/JDE.019.083. Epub 2019 Apr 8.


APOBEC Mutagenesis and Copy-Number Alterations Are Drivers of Proteogenomic Tumor Evolution and Heterogeneity in Metastatic Thoracic Tumors.

Roper N, Gao S, Maity TK, Banday AR, Zhang X, Venugopalan A, Cultraro CM, Patidar R, Sindiri S, Brown AL, Goncearenco A, Panchenko AR, Biswas R, Thomas A, Rajan A, Carter CA, Kleiner DE, Hewitt SM, Khan J, Prokunina-Olsson L, Guha U.

Cell Rep. 2019 Mar 5;26(10):2651-2666.e6. doi: 10.1016/j.celrep.2019.02.028.


Quantitative Mass Spectrometry to Interrogate Proteomic Heterogeneity in Metastatic Lung Adenocarcinoma and Validate a Novel Somatic Mutation CDK12-G879V.

Zhang X, Nguyen KD, Rudnick PA, Roper N, Kawaler E, Maity TK, Awasthi S, Gao S, Biswas R, Venugopalan A, Cultraro CM, Fenyö D, Guha U.

Mol Cell Proteomics. 2019 Apr;18(4):622-641. doi: 10.1074/mcp.RA118.001266. Epub 2019 Jan 7.


Meta-Analysis of Polymorphic Variants Conferring Genetic Risk to Cervical Cancer in Indian Women Supports CYP1A1 as an Important Associated Locus

Sengupta D, Guha U, Mitra S, Ghosh S, Bhattacharjee S, Sengupta M.

Asian Pac J Cancer Prev. 2018 Aug 24;19(8):2071-2081. Review.


Use of Virtual Comparison Software for Preparation Depth Assessment in a Dental Technique Skills Course.

Sadid-Zadeh R, Guha U, Arany H.

J Dent Educ. 2018 Aug;82(8):891-897. doi: 10.21815/JDE.018.085.


Dataset describing the development, optimization and application of SRM/MRM based targeted proteomics strategy for quantification of potential biomarkers of EGFR TKI sensitivity.

Awasthi S, Maity T, Oyler BL, Zhang X, Goodlett DR, Guha U.

Data Brief. 2018 May 2;19:424-436. doi: 10.1016/j.dib.2018.04.086. eCollection 2018 Aug.


Quantitative targeted proteomic analysis of potential markers of tyrosine kinase inhibitor (TKI) sensitivity in EGFR mutated lung adenocarcinoma.

Awasthi S, Maity T, Oyler BL, Qi Y, Zhang X, Goodlett DR, Guha U.

J Proteomics. 2018 Oct 30;189:48-59. doi: 10.1016/j.jprot.2018.04.005. Epub 2018 Apr 13.


Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors.

Thomas A, Redon CE, Sciuto L, Padiernos E, Ji J, Lee MJ, Yuno A, Lee S, Zhang Y, Tran L, Yutzy W, Rajan A, Guha U, Chen H, Hassan R, Alewine CC, Szabo E, Bates SE, Kinders RJ, Steinberg SM, Doroshow JH, Aladjem MI, Trepel JB, Pommier Y.

J Clin Oncol. 2018 Jun 1;36(16):1594-1602. doi: 10.1200/JCO.2017.76.6915. Epub 2017 Dec 18.


Association of 12 polymorphic variants conferring genetic risk to lung cancer in Indian population: An extensive meta-analysis.

Sengupta D, Guha U, Bhattacharjee S, Sengupta M.

Environ Mol Mutagen. 2017 Dec;58(9):688-700. doi: 10.1002/em.22149. Epub 2017 Oct 27.


Therapeutic Effects of XPO1 Inhibition in Thymic Epithelial Tumors.

Conforti F, Zhang X, Rao G, De Pas T, Yonemori Y, Rodriguez JA, McCutcheon JN, Rahhal R, Alberobello AT, Wang Y, Zhang YW, Guha U, Giaccone G.

Cancer Res. 2017 Oct 15;77(20):5614-5627. doi: 10.1158/0008-5472.CAN-17-1323. Epub 2017 Aug 17.


Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response.

Zhang X, Maity T, Kashyap MK, Bansal M, Venugopalan A, Singh S, Awasthi S, Marimuthu A, Charles Jacob HK, Belkina N, Pitts S, Cultraro CM, Gao S, Kirkali G, Biswas R, Chaerkady R, Califano A, Pandey A, Guha U.

Mol Cell Proteomics. 2017 May;16(5):891-910. doi: 10.1074/mcp.M117.067439. Epub 2017 Mar 22.


Consolidative local therapy in oligometastatic patients.

Kim C, Szabo E, Guha U, Rajan A.

Lancet Oncol. 2017 Feb;18(2):e61. doi: 10.1016/S1470-2045(17)30013-X. No abstract available.


Genomic profiling of multiple sequentially acquired tumor metastatic sites from an "exceptional responder" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response.

Biswas R, Gao S, Cultraro CM, Maity TK, Venugopalan A, Abdullaev Z, Shaytan AK, Carter CA, Thomas A, Rajan A, Song Y, Pitts S, Chen K, Bass S, Boland J, Hanada KI, Chen J, Meltzer PS, Panchenko AR, Yang JC, Pack S, Giaccone G, Schrump DS, Khan J, Guha U.

Cold Spring Harb Mol Case Stud. 2016 Nov;2(6):a001263.


Role of Local Ablative Therapy in Patients with Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer.

Kim C, Hoang CD, Kesarwala AH, Schrump DS, Guha U, Rajan A.

J Thorac Oncol. 2017 Feb;12(2):179-193. doi: 10.1016/j.jtho.2016.10.012. Epub 2016 Oct 22. Review.


EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models.

Venugopalan A, Lee MJ, Niu G, Medina-Echeverz J, Tomita Y, Lizak MJ, Cultraro CM, Simpson RM, Chen X, Trepel JB, Guha U.

Oncotarget. 2016 Aug 23;7(34):54137-54156. doi: 10.18632/oncotarget.11021.


Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers.

Rajan A, Kim C, Heery CR, Guha U, Gulley JL.

Hum Vaccin Immunother. 2016 Sep;12(9):2219-31. doi: 10.1080/21645515.2016.1175694. Epub 2016 May 2. Review.


Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.

Carter CA, Rajan A, Keen C, Szabo E, Khozin S, Thomas A, Brzezniak C, Guha U, Doyle LA, Steinberg SM, Xi L, Raffeld M, Tomita Y, Lee MJ, Lee S, Trepel JB, Reckamp KL, Koehler S, Gitlitz B, Salgia R, Gandara D, Vokes E, Giaccone G.

Ann Oncol. 2016 Apr;27(4):693-9. doi: 10.1093/annonc/mdw008. Epub 2016 Jan 22.


Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma.

Maity TK, Venugopalan A, Linnoila I, Cultraro CM, Giannakou A, Nemati R, Zhang X, Webster JD, Ritt D, Ghosal S, Hoschuetzky H, Simpson RM, Biswas R, Politi K, Morrison DK, Varmus HE, Guha U.

Cancer Discov. 2015 May;5(5):534-49. doi: 10.1158/2159-8290.CD-14-0750. Epub 2015 Mar 3.


Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.

Lopez-Chavez A, Thomas A, Rajan A, Raffeld M, Morrow B, Kelly R, Carter CA, Guha U, Killian K, Lau CC, Abdullaev Z, Xi L, Pack S, Meltzer PS, Corless CL, Sandler A, Beadling C, Warrick A, Liewehr DJ, Steinberg SM, Berman A, Doyle A, Szabo E, Wang Y, Giaccone G.

J Clin Oncol. 2015 Mar 20;33(9):1000-7. doi: 10.1200/JCO.2014.58.2007. Epub 2015 Feb 9.


Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins.

Poruchynsky MS, Komlodi-Pasztor E, Trostel S, Wilkerson J, Regairaz M, Pommier Y, Zhang X, Kumar Maity T, Robey R, Burotto M, Sackett D, Guha U, Fojo AT.

Proc Natl Acad Sci U S A. 2015 Feb 3;112(5):1571-6. doi: 10.1073/pnas.1416418112. Epub 2015 Jan 20.


ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomas.

Song X, Fan PD, Bantikassegn A, Guha U, Threadgill DW, Varmus H, Politi K.

Cancer Res. 2015 Mar 15;75(6):1035-45. doi: 10.1158/0008-5472.CAN-13-1625. Epub 2015 Jan 16.


Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.

Thomas A, Rajan A, Berman A, Tomita Y, Brzezniak C, Lee MJ, Lee S, Ling A, Spittler AJ, Carter CA, Guha U, Wang Y, Szabo E, Meltzer P, Steinberg SM, Trepel JB, Loehrer PJ, Giaccone G.

Lancet Oncol. 2015 Feb;16(2):177-86. doi: 10.1016/S1470-2045(14)71181-7. Epub 2015 Jan 13. Erratum in: Lancet Oncol. 2015 Mar;16(3):e105.


Identifying novel targets of oncogenic EGF receptor signaling in lung cancer through global phosphoproteomics.

Zhang X, Belkina N, Jacob HK, Maity T, Biswas R, Venugopalan A, Shaw PG, Kim MS, Chaerkady R, Pandey A, Guha U.

Proteomics. 2015 Jan;15(2-3):340-55. doi: 10.1002/pmic.201400315.


A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.

Kelly RJ, Thomas A, Rajan A, Chun G, Lopez-Chavez A, Szabo E, Spencer S, Carter CA, Guha U, Khozin S, Poondru S, Van Sant C, Keating A, Steinberg SM, Figg W, Giaccone G.

Ann Oncol. 2013 Oct;24(10):2601-6. doi: 10.1093/annonc/mdt249. Epub 2013 Jul 14.


SH3 domains: modules of protein-protein interactions.

Kurochkina N, Guha U.

Biophys Rev. 2013 Mar;5(1):29-39. doi: 10.1007/s12551-012-0081-z. Epub 2012 Jun 20. Review.


Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions.

Suehara Y, Arcila M, Wang L, Hasanovic A, Ang D, Ito T, Kimura Y, Drilon A, Guha U, Rusch V, Kris MG, Zakowski MF, Rizvi N, Khanin R, Ladanyi M.

Clin Cancer Res. 2012 Dec 15;18(24):6599-608. doi: 10.1158/1078-0432.CCR-12-0838. Epub 2012 Oct 10.


Keratinocyte expression of calcitonin gene-related peptide β: implications for neuropathic and inflammatory pain mechanisms.

Hou Q, Barr T, Gee L, Vickers J, Wymer J, Borsani E, Rodella L, Getsios S, Burdo T, Eisenberg E, Guha U, Lavker R, Kessler J, Chittur S, Fiorino D, Rice F, Albrecht P.

Pain. 2011 Sep;152(9):2036-51. doi: 10.1016/j.pain.2011.04.033. Epub 2011 Jun 17.


Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS.

Guha U, Chaerkady R, Marimuthu A, Patterson AS, Kashyap MK, Harsha HC, Sato M, Bader JS, Lash AE, Minna JD, Pandey A, Varmus HE.

Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):14112-7. doi: 10.1073/pnas.0806158105. Epub 2008 Sep 5.


Bone morphogenetic protein regulation of enteric neuronal phenotypic diversity: relationship to timing of cell cycle exit.

Chalazonitis A, Pham TD, Li Z, Roman D, Guha U, Gomes W, Kan L, Kessler JA, Gershon MD.

J Comp Neurol. 2008 Aug 10;509(5):474-92. doi: 10.1002/cne.21770.


Bone morphogenetic protein signaling regulates postnatal hair follicle differentiation and cycling.

Guha U, Mecklenburg L, Cowin P, Kan L, O'Guin WM, D'Vizio D, Pestell RG, Paus R, Kessler JA.

Am J Pathol. 2004 Sep;165(3):729-40.


Bone morphogenetic protein-2 and -4 limit the number of enteric neurons but promote development of a TrkC-expressing neurotrophin-3-dependent subset.

Chalazonitis A, D'Autréaux F, Guha U, Pham TD, Faure C, Chen JJ, Roman D, Kan L, Rothman TP, Kessler JA, Gershon MD.

J Neurosci. 2004 Apr 28;24(17):4266-82.


Target-derived BMP signaling limits sensory neuron number and the extent of peripheral innervation in vivo.

Guha U, Gomes WA, Samanta J, Gupta M, Rice FL, Kessler JA.

Development. 2004 Mar;131(5):1175-86.


In vivo evidence that BMP signaling is necessary for apoptosis in the mouse limb.

Guha U, Gomes WA, Kobayashi T, Pestell RG, Kessler JA.

Dev Biol. 2002 Sep 1;249(1):108-20.


Antisense ATM gene therapy: a strategy to increase the radiosensitivity of human tumors.

Guha C, Guha U, Tribius S, Alfieri A, Casper D, Chakravarty P, Mellado W, Pandita TK, Vikram B.

Gene Ther. 2000 May;7(10):852-8.

Supplemental Content

Support Center